Monday's Stocks to Watch: PDD, TXN, MCHP, and CF
Investors who bet against or avoided China technology stocks missed out on last week’s rally. After President Trump called for a 10% tariff on China, down from 60%, PDD (PDD) rallied by 7.05% to close at $111.34 on Jan 24, 2025.Investors may book trading profits on PDD, Alibaba (BABA), and JD (JD). China’s economy remains fragile, setting up negative economic trends in the near-term. The prospects for Chinese EV stocks are still mixed. XPeng (XPEV) closed near the high for the year while Nio (NIO) is near a low. Investors should consider a long-term position in Tesla (TSLA) stock instead.Texas Instruments (TXN) closed at $185.52, down by 7.52%. The firm posted $1.30 in earnings per share for the period ending Dec. 31, 2024. Revenue fell by 1.7% Y/Y. However, looking ahead, the chip company will earn $0.94 - $1.16 per share. This is below the $1.17 EPS estimate that analysts expected.Microchip (MCHP) dropped by 5.34% in sympathy to TXN stock.CF Industry Holdings (CF) lost 7.5% last Friday. J.P. Morgan Chase cut its rating on CF stock to a “Sell.” Analysts said that CF will have trouble growing its EBITDA and multiple when nitrogen product prices are flat or falling. Natural gas prices are rising, adding to CF’s raw material costs.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


